Trump’s Drug Pricing Victories Are A Winning Issue — If Republicans Use Them

(Photo by Nathan Howard/Getty Images)

President Trump has delivered real results on drug pricing, and our new national survey of likely voters makes clear those results are a political asset Republicans cannot afford to ignore heading into the 2026 midterms. 

The survey — conducted March 10–14, 2026, among 2,000 likely voters, with a margin of error of +/- 2.2% at a 95% confidence interval — reveals the scope of voters’ healthcare cost anxieties and the enormous political opportunity available to Republicans who move decisively to address them.

Start with the dominant concern: the cost of health insurance. Fifty-one percent (51%) of likely voters name it as their single biggest healthcare worry. Every other concern — hospital bills, drug costs, quality of care, access — is fragmented far behind. It is particularly acute among voters with private insurance, where 76% cite insurance costs as a top concern, and among seniors, where 71% do. These voters are not asking for sympathy. They are demanding action. (RELATED: Dems Who Clapped Like Seals For Biden’s Big Pharma Actions Do 180 On Trump Drug Pricing Order)

So what happens to a Republican candidate who supports President Trump’s call to end taxpayer subsidies for big insurance companies, and instead send that money directly to individuals to allow them to buy the health insurance of their choice?

Our poll found that voters are 61% more likely to vote for this candidate. Even more than 4 in 10 Democrats say they are more likely to vote for a Republican who supports giving the money directly to individuals to choose their own healthcare.

The left-wing media and Democratic critics have spent months trying to convince the public that the president’s voluntary Most Favored Nation (MFN) pricing agreements, also known as TrumpRx, are insufficient or ineffective. Our data says otherwise. Almost three-quarters of likely voters — 73% to 13% — support President Trump’s voluntary MFN pricing agreements with pharmaceutical manufacturers. By nearly a 2-to-1 margin (55% to 29%), voters say voluntary negotiations are more productive than the federal government dictating prices through laws or executive orders. 

A Republican candidate who supports these voluntary drug price deals is rewarded. Nearly 6 in 10 independent voters say they are more likely to vote for such a candidate. (RELATED: Trump Announces Dramatic Drop In Ozempic Price)

The president’s foreign freeloading message is also landing. Seventy-two percent (72%) of voters agree it is time to make other countries pay their fair share for prescription drugs — with near-universal backing among Republicans (92%) and strong majority support from Independents (65%) and Democrats (56%). The American people understand they have been subsidizing the rest of the world’s low drug prices for decades. They want it to stop. 

Here again, a Republican candidate is rewarded for supporting policies to lower drug costs. Our poll found that supporting legislation to end foreign freeloading makes voters 60% more likely to support a Republican congressional candidate.

There are many other opportunities for Republicans to pick up support in these midterm elections: Requiring insurance companies to pass along manufacturer discounts to patients (67% more likely), supporting giving every American the option of owning a Health Savings Account (59% more likely), and allowing seniors on Medicare to use manufacturer co-pay cards (65% more likely).  (RELATED: Trump Unveils Initiative To Claw Back Runaway Drug Prices)

President Trump changed the conversation on drug pricing. He brought pharmaceutical companies to the table, secured immediate savings for American patients, and is delivering on his promise to end foreign freeloading. Now the question is whether Republicans in Congress will seize the moment. If they want to hold their majorities in November, they cannot allow Democrats to own the healthcare affordability issue by default. The president has given them the playbook. The voters have told us it works. The only question is whether Congress will act.

Jim McLaughlin is a nationally recognized public opinion expert, strategic consultant and political strategist who has helped to elect a U.S. President, Prime Ministers, a Senate Majority Leader, and a Speaker of the House. Jim has worked for over 70 members of Congress, 14 U.S. Senators, 10 governors, numerous mayors and scores of other elected officials. He also serves as a consultant and market research strategist to Fortune 500 companies.

John McLaughlin has worked professionally as a strategic consultant and pollster for over 35 years. During this time he has earned a reputation for helping some of America’s most successful corporations and winning some of the toughest elections in the nation. His political clients have included former Presidential candidates Steve Forbes and Fred Thompson, former California Governor Arnold Schwarzenegger, former Florida Governor Jeb Bush, former Georgia Governor Nathan Deal and 22 current and former U.S. Senators and 18 current Republican members of Congress. Internationally John has worked for Israeli Prime Minister Benjamin Netanyahu, Hungarian Prime Minister Viktor Orban, and former Canadian Prime Minister Stephen Harper. In 2016, John worked as an advisor and pollster for Donald Trump from the primaries through Election Day. 

The views and opinions expressed in this commentary are those of the author and do not reflect the official position of the Daily Caller.

© The Daily Caller